Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance.
Explore this paper's citation graph
Summary
Emerging data suggest that patients with the highest chance of responding to TKIs should be selected on the basis of clinical and, most of all, biological characteristics, and Prospective trials are warranted to validate criteria for selection of patient selection for EGFR-inhibitors.
- Type
- article
- Published
- 2006-04-01
- Cited by
- 31
- References
- 51
- OpenAlex
- https://openalex.org/W16608980
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:10547489
Keywords
Sonication, Biology, Pollen, Apidae, Hymenoptera
References
- Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.
- The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
- Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer.
- Erlotinib in previously treated non-small-cell lung cancer
- Erlotinib in lung cancer - molecular and clinical predictors of outcome.
- Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
- Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
- Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
- The epidermal growth factor receptor and its inhibition in cancer therapy.
- Somatic mutations of EGFR in colorectal cancers and glioblastomas.
- Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage.
- Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.
- The EGF receptor family as targets for cancer therapy
- Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
- Anticancer drugs: To the rescue?
- O-242 Gefitinib (‘Iressa’, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer in IDEAL 1 and 2: tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone
- Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
- Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
- Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.
- Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Cited by
- Relationship between uptake of a radioiodinated quinazoline derivative and radiosensitivity in non-small cell lung cancer.
- 表皮生长因子/HER2抑制剂在非小细胞肺癌患者治疗中的作用综述
- Epidermal growth factor receptor (EGFR) gene copy number in colorectal adenoma-carcinoma progression.
- In-situ hybridization as a molecular tool in cancer diagnosis and treatment.
- Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs
- A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer.
- Paclitaxel-loaded polymeric micelle (230 mg/m(2)) and cisplatin (60 mg/m(2)) vs. paclitaxel (175 mg/m(2)) and cisplatin (60 mg/m(2)) in advanced non-small-cell lung cancer: a multicenter randomized phase IIB trial.
- Comparison of four antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in non-small cell lung cancer.
- EGFR-mutated lung cancer: a paradigm of molecular oncology
- Evaluation of 7q31 region improves the accuracy of EGFR FISH assay in non small cell lung cancer
- FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer
- The scaffolding protein NHERF1 sensitizes EGFR-dependent tumor growth, motility and invadopodia function to gefitinib treatment in breast cancer cells.
- Adding to the Mix: Fibroblast Growth Factor and Platelet-derived Growth Factor Receptor Pathways as Targets in Non–small Cell Lung Cancer
- The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells
- EGFR regulation by microRNA in lung cancer: a rose by any other name ... is an increasingly complicated rose.
- KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program
- EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment.
- Gefitinib efficacy in relapsed small-cell lung cancer.
- Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors.
- Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer
Related papers
- What's the 'buzz' about? The ecology and evolutionary significance of buzz-pollination.
- Buzz pollination in angiosperms.
- The functional significance of poricidal anthers and buzz pollination: controlled pollen removal from Dodecatheon
- Variability in bumblebee pollination buzzes affects the quantity of pollen released from flowers
- A biophysical model for buzz pollination in angiosperms.
- Sonication dispensing of pollen from Solanum laciniatum flowers
- The evolution of floral sonication, a pollen foraging behavior used by bees (Anthophila)
- Buzz foraging mechanism of bumble bees
- Bees assess pollen returns while sonicating Solanum flowers
- AN EXPERIMENTAL STUDY OF THE FLORAL ECOLOGY OF DODECATHEON MEADIA